NCT04502706 is a Phase 1 clinical trial of GS-0189 in Non-hodgkin Lymphoma, sponsored by Gilead Sciences.

Who is sponsoring NCT04502706?

NCT04502706 is sponsored by Gilead Sciences.

What drugs are being tested in NCT04502706?

Interventions in NCT04502706: GS-0189, Rituximab.

What condition does NCT04502706 study?

NCT04502706 studies Non-hodgkin Lymphoma.

Is NCT04502706 still recruiting?

NCT04502706 is currently terminated. Last updated 5 June 2023.

Last reviewed 2023-06-05 · How we verify

NCT04502706

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Terminated Phase 1 Last updated 5 June 2023

What this trial tests

Phase 1 trial testing GS-0189 in Non-hodgkin Lymphoma in 9 participants. Terminated before completion.

Timeline

17 November 2020

Primary endpoint
31 March 2022

31 March 2022

Quick facts

Lead sponsor	Gilead Sciences
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	17 November 2020
Primary completion	31 March 2022
Estimated completion	31 March 2022
Sites	5 locations across United States

Drugs / interventions tested

GS-0189 — full drug profile →
Rituximab — full drug profile →

Conditions studied

Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →

Sponsor

Gilead Sciences — full company profile →

Who can join

18 and older, any sex, with Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting macrophages in cancer immunotherapy.
Duan Z, Luo Y. · · 2021 · cited 462× · PMID 33767177 · DOI 10.1038/s41392-021-00506-6
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.
Guan F, Wang R, Yi Z, Luo P, et al · · 2025 · cited 155× · PMID 40055311 · DOI 10.1038/s41392-025-02124-y
CD47-SIRPα-targeted therapeutics: status and prospects.
Maute R, Xu J, Weissman IL. · · 2022 · cited 105× · PMID 35754851 · DOI 10.1016/j.iotech.2022.100070
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
Liu Y, Zhou X, Wang X. · · 2021 · cited 98× · PMID 34404434 · DOI 10.1186/s13045-021-01134-x
CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis.
Shi H, Wang X, Li F, Gerlach BD, et al · · 2022 · cited 71× · PMID 36417485 · DOI 10.1126/scitranslmed.abp8309
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
Qu T, Li B, Wang Y. · · 2022 · cited 66× · PMID 35418166 · DOI 10.1186/s40364-022-00373-5
Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC, Shi W, Shi JJ, Lu JJ. · · 2022 · cited 50× · PMID 34609596 · DOI 10.1007/s00432-021-03815-z
Cancer Therapy Targeting CD47/SIRPα.
Dizman N, Buchbinder EI. · · 2021 · cited 41× · PMID 34944850 · DOI 10.3390/cancers13246229

Verify or expand the search:

Other recruiting trials for Non-hodgkin Lymphoma

Currently open trials in the same condition.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06299462 — PTCy and ATG for MSD and MUD Transplants · Phase 1, PHASE2 · recruiting
NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C · EARLY_PHASE1 · recruiting
NCT06323525 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other Gilead Sciences trials

Trials by the same sponsor.

NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04502706 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 5 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04502706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing